Analysis of the 1992 Canadian population by risk group using the 2006 recommendations for the management of dyslipidemia*†
| Analysis | Low risk | Moderate risk | High risk | Total | Very high-risk subgroups
|
||
|---|---|---|---|---|---|---|---|
| History of CVD | History of diabetes, and age ≥30, years | 10-year risk of CAD >30% | |||||
| Estimated number (%) of individuals | 10,200,000 (82.9) | 790,000 (6.4) | 1,330,000 (10.7) | 12,350,000 (100.0) | 500,000 (4.0) | 390,000 (3.2) | 430,000 (3.5) |
| Number (%) recommended for lipid testing | 7,100,000 (69) | 790,000 (100) | 1,330,000 (100) | 9,200,000 (75) | 500,000 (100) | 390,000 (100) | 430,000 (100) |
| Number recommended for statin therapy | 150,000 | 430,000 | 1,275,000 | 1,900,000 | 470,000 | 370,000 | 430,000 |
| Percentage recommended statins of those screened | 2 | 55 | 96 | 20 | 95 | 94 | 100 |
| Number of CAD-related deaths prevented over 5 years§ | 155 | 1100 | 11,400 | 12,700 | 7200 | 1300 | 2900 |
| NNT to prevent 1 CAD-related death over 5 years of statin therapy§ | 1011 | 380 | 112 | 147 | 66 | 283 | 148 |
Raw numbers (before rounding) were used to calculate all percentages and the number needed to treat (NNT).
*The reference population included Canadians in 1992 20–74 years of age. Data from the Canadian Heart Health Survey were used to identify the risk categories of respondents;
†See Appendix 1 for risk group definitions;
§Calculated using Framingham study equations given a 24% relative efficacy of statins. CAD Coronary artery disease; CVD Cardiovascular disease